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Abstract
Sirt1 (member of the sirtuin family) is a nicotinamide adenosine dinucleotide (NAD)-dependent deacetylase that
removes acetyl groups from various proteins. Sirt1 performs a wide variety of functions in biological systems. The
current review focuses on the biological functions of Sirt1 in obesity-associated metabolic diseases, cancer, adipose
tissue, aging, cellular senescence, cardiac aging and stress, prion-mediated neurodegeneration, inflammatory
signaling in response to environmental stress, development and placental cell survival.
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Introduction
Sirt1 (mammalian) is a member of the sirtuin family [1].
It is a nicotinamide adenosine dinucleotide (NAD)-
dependent deacetylase and removes acetyl groups from
many histone and nonhistone proteins [2]. Sirt1 can
deacetylate a variety of substrates and is, therefore,
involved in a broad range of physiological functions,
including control of gene expression, metabolism and
aging [1,3,4]. Sirt1 catalyzes an enzymatic reaction that
generates nicotinamide and the acetyl group of the sub-
strate is transferred to cleaved NAD, generating a
unique metabolite, O-acetyl-ADP ribose [2]. The list of
Sirt1 substrates is continuously growing and includes
several transcription factors: the tumor suppressor pro-
tein p53, members of the FoxO family (forkhead box
factors regulated by insulin/Akt), HES1 (hairy and
enhancer of split 1), HEY2 (hairy/enhancer-of-split
related with YRPW motif 2), PPARg (peroxisome prolif-
erator-activated receptor gamma), CTIP2 [chicken oval-
bumin upstream promoter transcription factor
(COUPTF)- interacting protein 2], p300, PGC-1a
(PPARg coactivator), and NF-B (nuclear factor kappa
B) [1-4]. In this review we will discuss some of the most
relevant biological and pathophysiological functions of
Sirt1 [1].
Biological functions
Sirt1 and obesity-associated metabolic diseases
Hepatic metabolic derangements are key components in
the development of fatty liver, insulin resistance, and
atherosclerosis. Sirt1 is an important regulator of energy
homeostasis in response to nutrient availability. Scien-
tists demonstrated that hepatic Sirt1 regulates lipid
homeostasis by positively regulating peroxisome prolif-
erators-activated receptor a (PPARa), a nuclear receptor
that mediates the adaptive response to fasting and star-
vation. Hepatocyte-specific deletion of Sirt1 impairs
PPARa signaling and decreases fatty acid b-oxidation,
whereas overexpression of Sirt1 induces the expression
of PPARa targets. Sirt1 interacts with PPARa and is
required to activate PPARa coactivator PGC-1a.W h e n
challenged with a high-fat diet, liver-specific Sirt1
knockout (KO) mice develop hepatic steatosis, hepatic
inflammation, and endoplasmic reticulum stress [5]. Pre-
sent research data indicate that Sirt1 plays a vital role in
the regulation of hepatic lipid homeostasis and that
pharmacological activation of Sirt1 may be important
for the prevention of obesity associated metabolic dis-
eases [5]. Other research also shows that manipulation
of Sirt1 levels in the liver affects the expression of a
number of genes involved in glucose and lipid metabo-
lism [6]. Additionally, recent studies demonstrated that
modest overexpression of Sirt1 resulted in a protective
effect against high fat induced hepatic steatosis and glu-
cose intolerance [7,8]. Sirt1 orthologs also play a critical
role in controlling SREBP-dependent gene regulation
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response to fasting cues. These findings may have
important biomedical implications for the treatment of
metabolic disorders associated with aberrant lipid/cho-
lesterol homeostasis, including metabolic syndrome and
atherosclerosis [9]. Sirt1 regulates uncoupling protein 2
(UCP2) in beta cells to affect insulin secretion. Regula-
tion of UCP2 by Sirt1 may also be an important axis
that is dysregulated by excess fat to contribute to obesity
induced diabetes [10].
Sirt1 is a positive regulator of liver X receptor (LXR)
proteins [11,12], nuclear receptors that function as cho-
lesterol sensors and regulate whole-body cholesterol and
lipid homeostasis. LXR acetylation is evident at a single
conserved lysine (K432 in LXRa and K433 in LXRb)
adjacent to the ligand-regulated activation domain AF2
[2]. Sirt1 interacts with LXR and promotes deacetylation
and subsequent ubiquitination. Mutations of K432 elimi-
nate activation of LXRa by this sirtuin [11]. Loss of
Sirt1 in vivo reduces expression of a variety of LXR tar-
gets involved in lipid metabolism, including ABCA1, an
ATP-binding cassette (ABC) transporter that mediates
an early step of HDL biogenesis [2,11]. Altogether these
findings suggest that deacetylation of LXRs by Sirt1 may
be a mechanism that affects atherosclerosis and other
aging-associated diseases [11].
Above information suggests that Sirt1 is involved in
regulation of obesity-associated metabolic diseases
through regulating PGC-1a, UCP2 and LXR proteins.
Cancer and Sirt1
It has been shown that Sirt1 is significantly elevated in
human prostate cancer [13], acute myeloid leukemia
[14], and primary colon cancer [15]. Overexpression of
Sirt1 was frequently observed in all kinds of non-mela-
noma skin cancers including squamous cell carcinoma,
basal cell carcinoma, Bowen’s disease, and actinic kera-
tosis [16]. Based on the elevated levels of Sirt1 in can-
cers, it was hypothesized that Sirt1 serves as a tumor
promoter [17]. The first evidence of Sirt1 as a tumor
promoter came from experiments showing that Sirt1
physically interacts with p53 and attenuates p53-
mediated functions through deacetylation of p53 at its
C-terminal Lys382 residue [18,19]. In addition, two
r e c e n ts t u d i e sd e m o n s t r a t e dt h a tD B C 1( d e l e t e di n
breast cancer-1), which was initially cloned from a
region (8p21) homozygously deleted in breast cancer,
forms a stable complex with Sirt1 and inhibits Sirt1
activity, leading to increased levels of p53 acetylation
and upregulation of p53-mediated function. Consis-
tently, knockdown of DBC1 by RNA interference
(RNAi) promoted Sirt1 mediated deacetylation of p53
and inhibited p53-mediated apoptosis induced by geno-
toxic stress. These effects were reversed in cells by
concomitant RNAi-mediated knockdown of endogenous
Sirt1 [20,21]. Sirt1 is also involved in epigenetic silen-
cing of DNA-hypermethylated tumor suppressor genes
(TSGs) in cancer cells (Figure 1). Inhibition of Sirt1 by
multiple approaches (pharmacologic, over expression of
a dominant negative protein or short interfering RNA)
leads to TSG re-expression and a block in tumor-caus-
ing networks of cell signaling that are activated by loss
of the TSGs in a wide range of cancers. Furthermore,
Sirt1 inhibition causes re-expression of the E-cadherin
gene (in breast and colon cancer cell lines), whose pro-
tein product complexes with b-catenin, and this gene
reactivation collectively may suppress the constitutive
activation of the WNT signaling pathway [22]. Sirt1 acts
as a critical modulator of endothelial angiogenic func-
tions. Inhibition of endogenous Sirt1 gene expression
prevents the formation of a vascular-like network in
vitro. Overexpression of wild-type Sirt1, but not of a
deacetylase-defective mutant of Sirt1 (Sirt1 H363Y)
[18,19], increased the sproutforming and migratory
activity of endothelial cells [23].
DNA damage-induced acetylation of p53 protein leads
to its activation and either growth arrest or apoptosis.
In response to DNA damage, Sirt1 binds and deacety-
lates the p53 protein with specificity for its C-terminal
Lys382 residue, modification of which has been impli-
cated in the activation of p53 as a transcription factor.
Expression of wild-type Sirt1 in human cells reduces the
transcriptional activity of p53. In contrast, expression of
a catalytically inactive Sirt1 protein potentiates p53-
dependent apoptosis and radiosensitivity. So Sirt1 is
involved in the regulation of p53 function via deacetyla-
tion [18].
These data suggest that increased Sirt1 expression
and/or activity may increase the risk of cancer in
mammals by inhibiting p53 and potentially other
tumor suppressor genes. Human Sirt1 repression of
dihydrotestosterone (DHT) induced androgen receptor
(AR) signaling requires the NAD-dependent catalytic
function of Sirt1 and the AR lysine residues deacety-
lated by Sirt1.
Sirt1 inhibited coactivator-induced interactions
between the AR amino and carboxyl termini. DHT-
induced prostate cancer cellular contact-independent
growth is also blocked by Sirt1, providing a direct
functional link between Sirt1 and the AR, which is a
critical determinant of progression of human prostate
cancer [24].
On the other hand, other researchers analyzed a pub-
lic database and found that Sirt1 expression was reduced
in many other types of cancers, including glioblastoma,
bladder carcinoma, prostate carcinoma and ovarian can-
cers as compared to the corresponding normal tissues
[25]. Firestein et al demonstrated that overexpression of
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min/+ mice reduces, instead of increasing,
colon cancer formation. The data demonstrated that the
reduction in tumor development is caused by the ability
of Sirt1 to deacetylate b-catenin and promote cytoplas-
mic localization of the nuclear-localized oncogenic form
of b-catenin [26]. Recent investigations reported that
Sirt1 plays an important role in DNA damage repair
and in maintaining genome integrity (Figure 1). Analyz-
ing Sirt1 deficient mice, Wang et al found that Sirt1
-/-
embryos die at middle gestation stages, displaying
increased acetylation of H3K9 and H4K16, reduced
chromosome condensation, impaired heterochromatin
formation, and abnormal mitosis [25]. Sirt1
-/- cells dis-
played chromosome aneuploidy and structural aberra-
tions, conceivably originated from the continuous
division of abnormal mitosis. Sirt1 deficiency also causes
reduced ability to repair DNA-double strand breaks
(DSBs), radiation sensitivity, and impaired DDRs charac-
terized by diminished gH 2 A X ,B R C A 1 ,R A D 5 1a n d
NBS1 foci formation upon g-irradiation. Thus, Sirt1 may
play a role in recruiting these proteins to DNA damage
sites. Yuan et al d e m o n s t r a t e dt h a tS i r t 1p l a yar o l ei n
tumor suppression via c-Myc-Sirt1 feedback loop which
regulate c-Myc activity and cellular transformation. c-
M y cb i n d st ot h eS i r t 1p r o m o t e ra n di n d u c e sS i r t 1
expression. However, Sirt1 interacts with and deacety-
lates c-Myc, resulting in decreased c-Myc stability (Fig-
u r e1 ) .A sac o n s e q u e n c e ,c - M y c ’s transformational
capability is compromised in the presence of Sirt1 [27].
When Sirt1 was overexpressed in thymocytes in the p53
+/- model, after irradiation, there was a greater mean
survival and lower frequency of fatal thymic lymphomas
[28], further evidences of Sirt1 as a tumor suppressor.
These data provide strong evidence regarding Sirt1
that serves as a tumor suppressor. Thus, through
improving metabolic conditions by increasing Sirt1
activity, it is possible to both extend lifespan and reduce
cancer risk in humans in the foreseeable future [16].
Werner syndrome is an autosomal recessive disorder
associated with premature aging and cancer predisposi-
tion caused by mutations of the WRN gene. WRN is a
member of the RecQ DNA helicase family with
Figure 1 Activation and inhibition of many cellular processes by Sirt1.
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interacts with WRN both in vitro and in vivo; this inter-
action is enhanced after DNA damage. WRN can be
acetylated by acetyltransferase CBP/p300 and deacety-
lated by Sirt1 WRN acetylation decreases its helicase
and exonuclease activities: Sirt1 can thus reverse this
effect.
Moreover, WRN acetylation alters its nuclear distribu-
tion. Down-regulation of Sirt1 reduces WRN transloca-
tion from nucleoplasm to nucleoli after DNA damage.
This suggests that Sirt1 regulates WRN-mediated cellu-
lar responses to DNA damage through its deacetylation
and can help to prevent cancer [29].
The role of Sirt1 in cancer is still in controversy, it
could act as both tumor suppressor or tumor promoter.
This may depend on its targets or the cellular location
or specific cancers.
Adipose tissue and Sirt1
Adipose tissue recently emerged as a pivotal organ con-
trolling lifespan. Genetic manipulations aiming at modi-
fying fat mass also impact on the duration of life in
several model organisms [30]. Sirt1 represses peroxi-
some proliferator-activated receptors gamma transacti-
vation and inhibits lipid accumulation in adipocytes
(Figure 1). The effect of adipose tissue reduction on life-
span could be due to the production of adipokines act-
ing on target tissues such as the brain, or due to the
indirect prevention of age-related metabolic disorders
like type 2 diabetes or atherosclerosis [31]. Sirt1
improves insulin sensitivity, which has implications
toward resolving insulin resistance and type 2 diabetes
[32] (Figure 1).
Sirt1 represses PPARg by docking with its cofactors
NCoR (nuclear receptor corepressor) and SMRT (silen-
cing mediator of retinoid and thyroid hormone recep-
tors). Repression of PPARg by Sirt1 is also evident in
3T3-L1 adipocytes, where overexpression of Sirt1
attenuates adipogenesis, and RNA interference of Sirt1
enhances it. In differentiated fat cells, upregulation of
Sirt1 triggers lipolysis and loss of fat [33] (Figure 1).
Sirt1 is a functional regulator of PGC-1a that induces a
metabolic gene transcription program of mitochondrial
fatty acid oxidation [24].
Sirt1 and aging
Sirt1 and its ortholog appear to have a key role in deter-
mining lifespan of yeast, flies, and mice [34-36]. One
mechanism by which Sirt1 extends lifespan in the bud-
ding yeast, Saccharomyces cerevisiae, is by modifying the
physical structure (deacetylation) of key heterochroma-
tin regions of the genome, especially extrachomosomal
rDNA circles (ERCs), which accumulate in the nucleolus
[34,37,38]. This results in suppression of replication of
ERCs during each cell division (Figure 1). Budding
yeasts divide by asymmetric self-renewal where daughter
cells receive primarily newly synthesized organelles,
while mother cells preferentially retain “old” organelles
[37,38]. ERCs accumulate in mother cells in the nucleo-
lus as the mother cell continues to divide until 500 to
1000 copies of ERCs are present in the nucleolus,
usually after about 20 divisions. Then the nucleolus dis-
integrates and mother cells no longer grow/divide and
become quiescent. Thus, yeast mother cells have life-
span of approximately 20 divisions. Yeast cells contain-
ing an extra copy of the Sirt1 gene accumulate ERCs
more slowly because extra Sirt1 silent the rDNA region,
suppressing their formation and accumulation allowing
more divisions and longer lifespan than wild-type yeast
[34,37,38].
In human stem cells ageing is associated to telomere
erosion. In the absence of telomerase, telomere shorten-
ing occurs and eventually causes a change in chromatin
structure. This is recognized by the DNA-damage
response pathway and activates programmed cell death.
Sirt1 could have a role in telomere maintenance during
stem cell aging because of its essential role in gene
silencing [38]. Yeast SIR proteins are associated with tel-
omeres [38-40]. Maintenance of telomere stability via
histone deacetylation and chromatin stability modifica-
tions is also a potential mechanism by which Sirt1 could
influence stem cell aging and ultimately contribute to
longer lifespan [41] (Figure 1).
Another way Sirt1 could be involved in stem cell aging
via its central role in caloric restriction (CR)-induced
lifespan extension [42,43] and its link to age-related
reactive oxygen species (ROS) generation [44-46]; both
are highly dependent on mitochondrial metabolism.
ROS can damage macromolecules and lipids [47] and
accumulation of these damaged molecules over time is
believed to result in age-related decline in cell and tissue
function. The primary source of ROS in cells is mito-
chondria. ROS are a by-product of ATP generation via
the electron transport chain (ETC) and oxidative meta-
bolism. They are toxic and damaging at high concentra-
tions, but they are also essential for proper oxygen
sensing, maintenance of cellular redox state [48,49], and
regulation of proliferation and differentiation [50-52] at
lower concentrations. CR, known to extend lifespan in
several model organisms including yeast, flies, worms,
and rodents [42,46], appears to decrease ROS generation
in several mouse tissues by forcing mitochondrial repro-
gramming to preferentially generate ATP by b-oxidation
of fatty acids instead of carbohydrate catabolism. Sirt1
has been implicated in CR-induced lifespan extension in
mice (Figure 1) because Sirt1 gene deleted mice fail to
display at least some of the phenotypes of CR mice [53],
the most important of which is failure of CR to extend
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have a CR-like phenotype [55]. Furthermore, CR upre-
gulates Sirt1 in several mouse tissues and, importantly,
in human muscle tissue [56-58].
Sirt1 and cellular senescence
Cellular senescence is a state of permanent cell cycle
arrest, accompanied by defined morphological changes
that may be induced by several stimuli. Under certain
conditions, Sirt1 localizes to discrete nuclear substruc-
tures with PML (promyelocytic leukaemia) protein to
form nuclear bodies. PML may co-activate or corepress
various transcription factors localized in the nuclear
bodies, thus mediating different apoptotic signals. Up-
regulation of a PML isoform, PML-IV, recruits Sirt1
into the nuclear bodies together with p53. Thus, Sirt1
rescues primary mouse embryonic fibroblast from PML-
mediated premature cellular senescence by inhibiting
the pro-apoptotic action of p53 [59] (Figure 1). Mouse
embryonic fibroblasts lacking Sirt1 had an extended
replicative potential and showed greater proliferative
capacity following chronic but not lethal stress, a pheno-
type shown to require the tumor suppressor p19ARF
and its downstream target p53 [50,60]. A recent study
showed that Sirt1 levels are lower in cells that have
been serially split or in dividing tissues of aged mice,
such as thymus and testis, but not in immortalized cells
or post-mitotic organs [61].
Sirt1 in heart aging and stress
The prevalence of heart diseases, such as coronary artery
disease and congestive heart failure, increases with age.
Recent findings from transgenic mice with cardiac-speci-
fic overexpression of Sirt1 demonstrated a delayed aging
and protection against oxidative stress in the heart [62].
Low to moderate (about 3-fold to 8-fold) Sirt1 overex-
pression efficiently protected mice from paraquat-
induced cardiac stress and apoptosis, and delayed the
onset of age-dependent heart dysfunctions. Conversely,
greater increases in Sirt1 levels (about 13-fold) induced
oxidative stress and apoptosis, ultimately leading to car-
diomyopathy and decreased survival [63]. Several other
studies in mice models further demonstrated a protective
role of Sirt1 against hypertrophic and oxidative stresses
[64-66] (Figure 1). Loss of cardiomyocytes through apop-
tosis has been proposed as a cause of ventricular remo-
deling and heart failure. Ischemia and hypoxia-induced
apoptosis of cardiomyocytes reportedly plays an impor-
tant role in cardiac pathologies. Exposure of the cells to
resveratrol caused rapid activation of Sirt1, which had a
dual effect on FoxO1 function: Sirt1 increased FoxO1’s
ability to induce cell cycle arrest, but inhibited FoxO1’s
ability to induce cell death (Figure 1). This effect could
be reversed by Sirt1 inhibition. Results indicated that
resveratrol inhibits hypoxia-induced apoptosis via the
Sirt1 FoxO1 pathway in H9c2 cells. This polyphenol may
have potential in preventing cardiovascular disease, espe-
cially in coronary artery disease (CAD) patients [67].
Sirt1 also had a dual effect on FoxO3 function: Sirt1
increased FoxO3’s ability to induce cell cycle arrest and
resistance to oxidative stress but inhibited FoxO3’s ability
to induce cell death (Figure 1). Thus, one way through
which members of the Sir2 family of proteins may
increase organismal longevity is by tipping FoxO depen-
dent responses away from apoptosis and toward stress
resistance [51]. Sirt1 also deacetylates and represses the
activity of the FoxO3a and other mammalian forkhead
factors. This regulation appears to be in the opposite
direction in respect to the genetic interaction of Sir2 with
forkhead in C. elegans. By restraining mammalian fork-
head proteins, Sirt1 also reduces forkhead-dependent
apoptosis [68].
Sirt1 in prion-mediated neurodegeneration
S i r t 1p l a y sap r o t e c t i v er o l ei ns e v e r a lm o d e l so fn e u r o -
degenerative disease. Sirt1 may serve as a downstream
effector of increased NAD biosynthesis and delay axonal
degeneration in a mouse model of Wallerian degenera-
tion [69]. Importantly, overexpression of Sirt1 also pro-
tects against Alzheimer’s disease, Huntington’sd i s e a s e
and amyotrophic lateral sclerosis in various model sys-
tems [70-73] (Figure 1), consistent with its proposed
neuroprotective function. Prion diseases are unique
among neurodegenerative diseases in that they are
transmissible while still sharing commonalities with
other neurodegenerative diseases such as the accumula-
tion of aggregates of misfolded protein, a prominent
astrocytic and microglial response, and loss of neurons
in the central nervous system [74]. Research report
show that the onset of prion disease is delayed by CR
and in the Sirt1 KO mice fed ad libitum (Figure 1). CR
exerts no further effect on the Sirt1 KO strain, suggest-
ing the effects of CR and Sirt1 deletion are mechanisti-
cally coupled. In conjunction, Sirt1 is downregulated in
certain brain regions of CR mice [75].
Sirt1 inhibition increased acetylation and decreased
phosphorylation of IRS-2; it also reduced activation of
the Ras/ERK1/2 pathway, suggesting that Sirt1 may
enhance IGF-I signaling in part by deacetylating IRS-2
[76]. Either the inhibition of Sirt1 or of Ras/ERK1/2 was
associated with resistance to oxidative damage. Markers
of oxidized proteins and lipids were reduced in the
brain of old Sirt1 deficient mice, but the lifespan of the
homozygote knockout mice was reduced under both
normal and calorie-restricted conditions [76]. These
findings are consistent with findings in S. cerevisiae and
other model systems, suggesting that mammalian sir-
tuins can play both protective and proaging roles [76].
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environmental stress
Researchers have determined that Sirt1 provides protec-
tion against chronic inflammation by controlling the
acetylation of nuclear factor kappa B (NF-B), a tran-
scription signaling pathway involved in the innate
immune response (Figure 1). Generation of myeloid-spe-
cific Sirt1 knockout mouse model (Mac-Sirt1 KO) and
demonstrated that the absence of Sirt1 resulted in
hyperacetylated NF-B, which led to an increase in the
transcription of proinflammatory genes in macrophages
[77]. Using bone marrow-derived macrophages from
wild-type and Mac-Sirt1 KO mice, the investigators con-
firmed their results in vitro [77]. The Mac-Sirt1 KO
cells also exhibited hyperacetylated NF-B levels [77].
Taken together, the above findings demonstrate Sirt1
as an important mediator between environmental stress
and immune system activation [77]. Sirt1 also limits
replicative lifespan in response to chronic genotoxic
stress [50] (Figure 1).
Development and Sirt1
High levels of Sirt1 mRNA are detectable in heart, brain,
spinal cord and dorsal root ganglia of embryos, indicat-
ing that it may play a critical role in development [78].
Consistent with this, Sirt1 knockout mice show develop-
mental defects. About half of the numbers of pups
expected are typically born, and of these approximately
20% survive to adulthood. Sirt1 knockout mice are also
markedly smaller than their littermates, develop more
slowly and show dramatic perturbations in eye morpho-
genesis and cardiac septation [79]. Both males and
females that survive to adulthood are sterile, males have
low sperm counts and females fail to ovulate, which is
probably due to a hormonal inefficiency [79,53] (Figure
1). Sirt1 KO models differ enormously in their pheno-
type accordingly to the genetic background. Their life-
span ranges from few weeks to two years [65].
Explanations for these phenotype of the knockouts
may come from biochemical studies. The Hairy and Hey
subfamilies of the bHLH (basic helix-loop-helix) pro-
teins primarily function as transcriptional repressors
that direct metazoan development [80]. The mammalian
homologue of Drosophila Hairy is Hes1 and of Hey is
Hey2. Sirt1 interacts with Hes1 and Hey2, both in vivo
and in vitro, and modulates their ability to repress target
promoters [1]. Sirt1 also interacts with mammalian and
chicken protein BCL11A and CTIP2, respectively, which
are involved in haematopoietic cell development and
malignances [81].
Sirt1 in placental cell survival
Sirt1 is upregulated in primary trophoblasts from
human placenta exposed to hypoxia and enhances the
expression of the NDRG1 (N-Myc down-regulated gene
1), which inhibits p53 transcription. Therefore by direct
inactivation of p53 or by reducing its expression via
NDRG1, Sirt1 promotes cell resistance to oxygen defi-
ciency in the placenta [1] (Figure 1). Moreover, the
expression of NDRG1 in hypoxia was reduced by sirti-
nol, which inactivates Sirt1 [66]. Neither overexpression
nor silencing of NDRG1 influenced Sirt1 expression.
These results provide further support to the protective
function of NDRG1 in hypoxia, implicating Sirt1/p53
signaling in the process [82].
Perspectives
When Sir2 was first discovered in yeast 27 years ago, it
could hardly have been anticipated how much interest
would be taken in this family of proteins [1]. Several
studies over the last 10 years have illuminated our
understanding of the role of sirtuins in different organ-
isms. Currently, biological functions of Sirt1 range from
DNA repair to aging. Yet many questions remain to be
answered. Further research will give us a far clearer per-
spective as to whether the sirtuins may provide novel
therapies to alleviate age-associated changes, such as
diabetes, cancer and cardiovascular disease, and possibly
extend healthy human lifespan.
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